Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study. - Wikidata - awgldk - TriplyDB

Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.

Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.

http://www.wikidata.org/entity/Q37575938

about

Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.

http://www.wikidata.org/entity/Q37575938

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Acute lymphoblastic leukemia r ...... a retrospective GRAALL study.

@en

Acute lymphoblastic leukemia r ...... a retrospective GRAALL study.

@nl

type

label

Acute lymphoblastic leukemia r ...... a retrospective GRAALL study.

@en

Acute lymphoblastic leukemia r ...... a retrospective GRAALL study.

@nl

prefLabel

Acute lymphoblastic leukemia r ...... a retrospective GRAALL study.

@en

Acute lymphoblastic leukemia r ...... a retrospective GRAALL study.

@nl

P1433

Q37575938-E2832036-1E6E-4198-9A63-6806011456B0

P1476

Q37575938-2C058C24-FF7E-4A32-972D-68CC5AD2A3DE

P2093

Q37575938-069972DE-50BE-49FD-B95C-2C208215C776

Q37575938-18BB476F-61EB-4309-B645-E631F97AEFBC

Q37575938-1D2E17BA-CFAF-4AB7-BCD3-855D5F4E923F

Q37575938-28E8C525-6F89-4235-AC16-B8575EFEFE9C

Q37575938-2F8D65EF-C87F-4C4B-8F48-54AC620DEFD4

Q37575938-38BAEE5C-7001-4A6E-A8B6-35BD21B2590F

Q37575938-4B104A50-7D5A-4049-99B3-D475516BC8BC

Q37575938-51E179B2-22BC-4F09-B130-9810B254F849

Q37575938-5C24BCBF-4D0B-4DF8-86F3-79241FA78D1B

Q37575938-6197ADB3-24C4-4F31-A20D-96B0C979E9D7

P2860

Q37575938-07BDD00E-0442-4433-9F29-ED6AB9197A7B

Q37575938-1BBCF19C-2553-4938-BC56-A903E1AA32DD

Q37575938-1C51E8CD-C6BA-49B8-AFD1-CA56F259EAF3

Q37575938-1FF72BD4-58B2-4C77-8A27-5AEA49BFFC8C

Q37575938-22333C76-3D38-4DFD-A13D-7F460CC69D44

Q37575938-2685BBB9-448C-4FA3-9AC1-98E5E9BFC635

Q37575938-283EF09F-FC7E-4C77-AFC9-6BFC850795B2

Q37575938-352111ED-EA2A-499A-9750-5DB47BA284C8

Q37575938-42C3F783-1E5D-4522-924F-EE36C5EFB292

Q37575938-458F01F2-6C08-4320-AAF8-D268F365EDBE

P2888

Q37575938-B482D09F-56C1-4F7F-A35A-610B67B1B69F

P304

Q37575938-C1F0B984-48EC-4506-B9E3-7DEF7611CD75

P31

Q37575938-DEFC7614-D110-4FBC-AAB3-1F0343DAFD09

P356

Q37575938-A0252249-20DA-44E7-863D-09FC7079AF2A

P433

Q37575938-C6E4563F-7CE9-4B01-856B-3654CC5E50FF

P478

Q37575938-E07DCC37-E43D-4E5E-830F-BC2ECF9FDF84

P50

Q37575938-AA512CCD-96C1-4717-ACC8-3BA787F43492

P577

Q37575938-D6AB1F49-3B34-4D74-9B3F-671DDCF8B436

P6179

Q37575938-66039982-4277-4F14-9FF4-174C45B22E02

P698

Q37575938-C2FB6E30-C3CE-4FDD-8D7C-AABA5A10270E

P932

Q37575938-50AC3E77-ED6C-4048-94AB-3B40F1CFD24D

P356

P1433

Blood Cancer Journal

P1476

Acute lymphoblastic leukemia r ...... a retrospective GRAALL study.

@en

P2093

A Charbonnier

http://www.w3.org/2001/XMLSchema#string

A Desjonquères

http://www.w3.org/2001/XMLSchema#string

B Lioure

http://www.w3.org/2001/XMLSchema#string

C Himberlin

http://www.w3.org/2001/XMLSchema#string

E Tavernier

http://www.w3.org/2001/XMLSchema#string

F Huguet

http://www.w3.org/2001/XMLSchema#string

F Isnard

http://www.w3.org/2001/XMLSchema#string

H Dombret

http://www.w3.org/2001/XMLSchema#string

J-N Bastié

http://www.w3.org/2001/XMLSchema#string

J-O Bay

http://www.w3.org/2001/XMLSchema#string

P2860

Nonparametric Estimation from Incomplete Observations

The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemia

IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.

Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia.

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.

NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.

The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression.

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.

P2888

P304

e504

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BCJ.2016.111

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-12-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1051503926

http://www.w3.org/2001/XMLSchema#string

P698

27935576

http://www.w3.org/2001/XMLSchema#string

P932

5223147

http://www.w3.org/2001/XMLSchema#string